Cogent Biosciences, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for genetically defined diseases. The company's business model centers on identifying well-understood genetic mutations that drive diseases, such as cancers and rare disorders, and developing targeted small molecule therapeutics to address them. As a pre-revenue, clinical-stage entity, Cogent does not currently generate product revenue and relies on equity financing and debt facilities to fund its extensive research and development activities.
The company's lead clinical asset is bezuclastinib, a highly selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation, which drives systemic mastocytosis, as well as other KIT exon 17 mutations found in advanced gastrointestinal stromal tumors (GIST). Cogent is advancing bezuclastinib through multiple late-stage clinical trials, including the APEX, SUMMIT, and PEAK studies, and is actively pursuing regulatory approvals. Beyond its lead asset, Cogent's research team is advancing a robust preclinical and early-stage clinical pipeline of novel targeted therapies. This includes programs targeting mutations in FGFR2, ErbB2, PI3Kα, JAK2, and KRAS.
Headquartered in Waltham, Massachusetts, with a dedicated discovery research facility in Boulder, Colorado, Cogent operates primarily in the United States but conducts clinical trials internationally. The company competes in the highly specialized precision oncology and rare disease markets, differentiating itself through its focus on rational drug design and highly selective kinase inhibitors aimed at overcoming the limitations and safety concerns of existing treatments.
